Omeprazole produces parietal cell hypertrophy and hyperplasia in humans
Tóm tắt
While there is evidence that omeprazole may induce changes in parietal cells, the effect of acid suppression on parietal cells in humans is poorly documented. This study was undertaken to evaluate the effects of omeprazole in human parietal cells over time. The light microscopic morphology of parietal cells in gastric biopsies from 17 patients on omeprazole were compared with those from 13 patients on ranitidine and 20 patients on no acid-lowering medication. Light microscopic and ultrastructural morphology of parietal cells was also evaluated in an additional 14 patients before and after omeprazole administration. Objective measurements of parietal cell height, mass and number were analyzed using analyses of variance. Electron microscopy was used to evaluate parietal cell enlargement. Twenty-five of 31 biopsies from patients on omeprazole, 1 of 13 from patients on ranitidine, and 0 of 20 from patients on neither drug showed parietal cell enlargement. Parietal cell height, mass, and number were increased in omeprazole-treated patients compared with ranitidine-treated patients and those on neither drug, and with the group also evaluated prior to beginning omeprazole treatment. Parietal cell height and mass were increased in patients on omeprazole longer than 12 months compared with biopsies from patients on the drug for less than 12 months. Resin-embedded sections and electron microscopy showed enlarged parietal cells with prominence of cytoplasmic tubulovesicles with sparse secretory canaliculi. Parietal cell hypertrophy and hyperplasia develops in patients on chronic omeprazole therapy; this can be recognized on routine examination of histologic sections. These morphologic changes increase with duration of therapy.
Tài liệu tham khảo
Massoomi F, Savage J, Destache CJ: Omeprazole: A comprehensive review. Pharmacotherapy 13:46–59, 1993
Sachs G, Wallmark B: The gastric H+,K+-ATPase: The site of action of omeprazole. Scand J Gastroenterol Suppl 24:3–11, 1989
Arens MJ, Dent J: Acid pump blockers: What are their current therapeutic roles? Bailliere's Clin Gastroenterol 7:95–128, 1993
Solcia E, Rindi G, Silini E, Villani L: Enterochromaffin-like (ECL) cells and their growths: Relationships to gastrin, reduced acid secretion and gastritis. Bailliere's Clin Gastroenterol 7:149–65, 1993
Helander HF, Rutgersson K, Helander KG, Pisegna JP, Gardner JD, Maton PN: Stereologic investigations of human gastric mucosa. II. Oxyntic mucosa from patients with Zollinger-Ellison syndrome. Scand J Gastroenterol 27:875–883, 1992
Helander HF, Simonsson M, Sundler F, Rutgersson K, Helander KG, Eriksson S: Histology of gastric biopsies from peptic ulcer patients before and after short-term treatment with omeprazole or H2-receptor antagonists. Virchows Arch A Pathol Anat Histopathol 417:305–309, 1990
Stachura J, Konturek SJ, Cieszkowsky M, Dabros W, Zakrzewska J: Comparison of the effect of omeprazole—a substituted benzimidazole—and ranitidine—a potent H2-receptor antagonist—on histamine-induced gastric acid secretion and the ultrastructure of canine parietal cells. Hepatogastroenterology 30:205–210, 1983
Brenna E, Waldum HL, Sandvik AK, Schulze Sognen B, Kristensen A: Effects on the rat oxyntic mucosa of the histamine-antagonist loxtidine and the H+ K+-ATPase inhibitor omeprazole. Aliment Pharmacol Ther 6:335–349, 1992
Blom H: Alterations in gastric mucosal morphology induced by long-term treatment with omeprazole in rats. Digestion 35:98–105, 1986
Safholm C, Havu N, Forssell H, Sundell G, Mattsson H: Effect of 7 years' daily oral administration of omeprazole to beagle dogs. Digestion 55:139–147, 1994
Helander HF, Sundell GW: Ultrastructure of inhibited parietal cells in the rat. Gastroenterology 87:1064–1071, 1984
Karasawa H, Tani N, Miwa T: The effect of omeprazole on ultrastructural changes in gastric parietal cells. Gastroenterol Jpn 23:1–8, 1988
Furuhashi M, Nakahara A, Fukutomi H, Kominami E, Uchiyama Y: Changes in subcellular structures of parietal cells in the rat gastric gland after omeprazole. Arch Histol Cytol 55:191–201, 1992
Inokuchi H, Kawai T, Hattori T, Kawai K: Omeprazole causes parietal cell damage, DNA synthesis and cellular proliferation in rat oxyntic mucosa. Eur J Gastroenterol Hepatol 4:207–214, 1992
Helander HF, Mattsson H, Elm G, Ottosson S: Structure and function of rat parietal cells during treatment with omeprazole, SCH 28080, SCH 32651, or ranitidine. Scand J Gastroenterol 25:799–809, 1990
Helander HF: Parietal cell structure during inhibition of acid secretion. Scand J Gastroenterol Suppl 101:21–26, 1984
Karam SM, Forte JG: Inhibiting gastric H(+)-K(+)-ATPase activity by omeprazole promotes degeneration and production of parietal cells. Am J Physiol 266:G745-G758, 1994
Kato S, Fujii T, Nakano K, Naganuma H, Nakagawa H: The effects of omeprazole on the ultrastructure of gastric parietal cells. J Pediatr Gastroenterol Nutr 19:91–96, 1994
Fryklund J, Helander HF, Elander B, Wallmark B: Function and structure of parietal cells after H+-K+-ATPase blockade. Am J Physiol 254:G399-G407, 1988
Stolte M, Bethke B, Ruhl G, Ritter M: Omeprazole-induced pseudohypertrophy of gastric parietal cells. Z Gastroenterol 30:134–138, 1992
Ang ST, Lieberman DA, Ippoliti AF, Weber L, Weinstein WM: Long term omeprazole therapy in patients with Barrett's esophagus is associated with parietal cell hyperplasia. Gastroenterology 106:A1016, 1994 (abstract)
Weinstein WM, Ang ST, Ippoliti AF, Lieberman DA: Fundic gland polyps in patients on long term omeprazole therapy: A light and electron microscopic study of the gastric mucosa. Gastroenterology 106:A210, 1994 (abstract)
Hassall E, Dimmick J, Israel D: Parietal cell hyperplasia in children receiving omeprazole. Gastroenterology 108:A110, 1995
Lee SW, Lieberman DA, Ippoliti AF, Hsieh CY, Weinstein WM: Changes in the parietal cell mass after long term therapy with high dose omeprazole in Barrett's esophagus (BE): A two year prospective study. Gastroenterology 110:A173, 1996 (abstract)
Scott DR, Besancon M, Sachs G, Helander H: Effects of antisecretory agents on parietal cell structure and H/K-ATPase levels in rabbit gastric mucosain vivo. Dig Dis Sci 39:2118–2126, 1994
Graham JR: Gastric polyposis: onset during long-term therapy with omeprazole. Med J Aust 157:287–288, 1992
Hirt M, Lee SW, Weinstein WM: Fundic gland polyps: A comparison of the omeprazole-associated and the sporadic types. Gastroenterology 110:A135, 1996 (abstract)
Lee RMKW: A critical appraisal of the effects of fixation, dehydration and embedding or cell volume.In The Science of Biological Specimen Preparation for Microscopy and Microanalysis. Revel J, Barnard T, Haggis GH (eds). O'Hare, Illinois, Scanning Electron Microscopy, Inc., 1984, pp 61–70
Helander HF, Hirschowitz BI: Quantitative ultrastructural studies on gastric parietal cells. Gastroenterology 63:951–961, 1972
Ito S, Schofield GC: Studies on the depletion and accumulation of microvilli and changes in the tubulovesicular compartment of mouse parietal cells in relation to gastric acid secretion. J Cell Biol 63:364–382, 1974
Forte TM, Machen TE, Forte JG: Ultrastructural changes in oxyntic cells associated with secretory function: A membrane-recycling hypothesis. Gastroenterology 73:941–955, 1977
Carlsson E, Larsson H, Mattsson H, Ryberg B, Sundell G: Pharmacology and toxicology of omeprazole—with special reference to the effects on the gastric mucosa. Scand J Gastroenterol Suppl 21:31–38, 1986
Lind T, Cederberg C, Ekenved G, Haglund U, Olbe L. Effect of omeprazole—a gastric proton pump inhibitor—on pentagastrin stimulated acid secretion in man. Gut 24:270–276, 1983
Sharma B, Axelson M, Pounder RP, Lundborg P, Ohman M, Santana A, Talbot M, Cederberg C: Acid secretory capacity and plasma gastrin concentration after administration of omeprazole to normal subjects. Aliment Pharmacol Ther 1:67–76, 1987
Sharma BK, Walt RP, Pounder RE, Gomes Md, Wood EC, Logan LH: Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity. Gut 25:957–964, 1984
Lamberts R, Creutzfeldt W, Struber HG, Brunner G, Solcia E: Long-term omeprazole therapy in peptic ulcer disease: Gastrin, endocrine cell growth, and gastritis. Gastroenterology 104:1356–1370, 1993
Logan RPH, Walker MM, Misiewicz JJ, Gummett PA, Karim QN, Baron JH: Changes in the intragastric distribution ofHelicobacter pylori during treatment with omeprazole. Gut 36:12–16, 1995
Stolte M, Baumann K, Bethke B, Ritter M, Lauer E, Eidt H: Active autoimmune gastritis without total atrophy of the glands. Z Gastroenterol 30:729–735, 1992